Tue, Aug. 25, 5:35 PM
- investors should stick with "market darlings" - the 25 stocks that had performed the best during the six months before a market pullback - according to the analyst team at RBC.
- The firm notes that although many recent winners are leading the market lower, the extent of the underperformance is just 1%; it also says investing in the group following sharp market pullbacks is a winning strategy over the ensuing week, month and six months.
- RBC's 25 market darlings are AET, ALTR, AMZN, AIZ, CVC, CI, CAG, EA, EQIX, EXPE, GME, GOOGL, HAS, HCA, MNST, NFLX, NKE, PRGO, REGN, SBUX, TSO, TWC, TSS, UA, UHS
Fri, Aug. 7, 1:58 AM
- U.S. hospitals are now urging antitrust regulators to seriously debate Anthem's (NYSE:ANTM) planned acquisition of rival Cigna (NYSE:CI).
- In a letter to the DOJ, the American Hospital Association said combining the country's No. 1 and No. 5 health insurers would reduce competition in 817 geographic markets serving 45M consumers.
- Anthem announced the $47B plans just weeks after Aetna inked a deal with Humana, reducing the number of national insurers to three from five.
Thu, Jul. 30, 1:37 PM
- Unsurprisingly, Express Scripts (ESRX -0.6%) takes a dim view of the proposed price of the cholesterol-lowering PCSK9 inhibitor Praluent (alirocumab). Last Friday, co-developers Sanofi (SNY +1.6%) and Regeneron Pharmaceuticals (REGN +0.4%) announced that the wholesale acquisition cost (WAC) of the once-every-two-week injection will be $40 per day or $14,600 per year. This is several orders of magnitude above the cost of statins, which average $2 - 3 per day.
- WAC is the average price that wholesalers and distributors pay for the drug. Patients will, of course, pay quite a bit more.
- Pharmacy benefit managers, still feeling the pinch from Gilead's (GILD +1.8%) HCV meds Sovaldi and Harvoni, will likely ratchet up their opposition as Praluent's U.S. launch commences.
- Related tickers: (AET +0.9%)(CTRX)(CNC +0.9%)(CI -0.7%)(HUM)(MRK +0.3%)(OCR +0.4%)(UNH -0.7%)(CVS -0.5%)
Thu, Jul. 30, 11:08 AM
- CIGNA (CI -0.42%) Q2 results: Operating Revenues: $9,471M (+9.3%); Premiums: $7,432M (+9.3%); Fees: $1,057M (+10.3%); Net Income: $588M (+2.6%); EPS: $2.26 (+6.6%); Adjusted income from operations: $2.55M (+23.2%).
- Customers: Global Medical: 14,771 (+3.7%); Commercial: 14,215 (+3.3%); Behavioral Care: 24,164 (+4.8%); Dental: 13,818 (+3.9%); Pharmacy: 7,905 (+7.3%); Medical Part D: $14,58 (+20.7%).
- 2015 Guidance: Revenue growth: 8 - 10%; non-GAAP operating income: $2.16B - 2.24B; non-GAAP operating income per share: $8.30 - 8.60.
Thu, Jul. 30, 6:04 AM
Wed, Jul. 29, 5:30 PM
- AAWW, AB, ACI, ACIW, ACOR, ACRE, ADP, ALKS, ALLE, ALU, ALXN, AMRC, APD, AVP, AWI, AZN, BC, BCO, BG, BLL, BUD, BWA, BWEN, CAH, CBB, CBM, CBR, CCE, CCJ, CEVA, CI, CL, CME, COP, COT, CPN, CRL, CRR, CRS, CSH, CVE, CVI, CVRR, DBD, DCIX, DFT, DLPH, EDR, EME, ENTG, EPD, ERJ, ESI, EXLS, FCAU, FCN, FIG, FMS, GG, GHM, GLOP, GLPI, GNC, GOV, GTLS, GVA, HEES, HOT, HP, HST, I, IART, IDA, IDCC, IDXX, INGR, IRDM, IRM, IT, ITC, IVZ, KMT, LBY, LINE, LKQ, LLL, MD, MDLZ, MDP, MDXG, MMYT, MOBL, MPC, MPLX, MSCI, MTRN, MWW, NAVB, NICE, NMM, NNN, NOK, NTCT, ODFL, OSK, OXY, PBI, PCRX, PES, PF, PG, PNK, PNW, POT, PRFT, PWE, RDS.A, RFP, RTIX, RYAM, RYL, SC, SCG, SEE, SHOO, SHOP, SMP, SNE, SNMX, SSYS, SUI, SWK, TASR, TDY, TE, TEX, TFX, TKR, TMUS, TWC, TWI, UAN, UFS, UPL, VA, VG, VICL, VLO, VLY, WST, WWE, XEL, XRAY, XYL, YNDX, ZBH
Tue, Jul. 28, 1:41 PM
- Teladoc (TDOC -2.2%) initiated with Overweight rating and $38 price target by JP Morgan; a Buy rating and $38 (23% upside) price target by Deutsche Bank; a Buy rating and $37 price target by SunTrust Bank and an Outperform rating by William Blair.
- Natera (NTRA +0.1%) initiated with Equal Weight rating and $20 (11% upside) price target by Morgan Stanley.
- Aegerion Pharmaceuticals (AEGR +9.4%) upgraded to Buy from Hold by Jefferies. Price target maintained at $26 (30% upside).
- Centene (CNC) upgraded to Buy from Neutral by UBS. Price target maintained at $80 (16% upside).
- Biogen (BIIB +2.4%) upgraded to Outperform from Market Perform by Bernstein. Price target lowered to $385 (21% upside) from $436.
- Anthem (ANTM +1.3%) upgraded to Buy from Neutral with $185 (21% upside) price target by Sterne Agee CRT. Cigna (CI -0.2%) also upgraded to Buy with a $190 (30% upside) price target.
- Alexion Pharmaceuticals (ALXN +2.6%) upgraded to Overweight from Not Rated by JP Morgan. Price target is $249 (23% upside).
- IGI Labs (IG +0.5%) upgraded to Buy from Neutral by Roth Capital. Price target raised to $11 from $7 (18% downside risk).
- Omnicare (OCR +0.3%) downgraded to Neutral from Overweight by JP Morgan. Price target lowered to $90 (6% downside risk) from $98.
- Ultragenyx (RARE +3.4%) downgraded to Equal Weight from Overweight by Morgan Stanley. Price target raised to $126 (5% upside) from $77.
- Biogen (BIIB +2.1%) downgraded to Neutral by Baird. Price target lowered to $316 (0% upside) from $480.
- Sunesis Pharmaceuticals (SNSS +21%) downgraded to Sell from Buy by Roth Capital Partners. Price target lowered to $1 (22% downside risk) from $5.50.
Fri, Jul. 24, 6:15 AM
- Anthem (NYSE:ANTM) has agreed to buy Cigna (NYSE:CI) in a deal valued at $54.2B, wrapping up a year of negotiations and creating the largest health insurer in the U.S.
- Cigna shareholders will get $103.40 per share in cash and 0.5152 Anthem shares.
- The deal comes three weeks after Aetna (NYSE:AET) struck a deal to buy Humana (NYSE:HUM) for $37B and is part of an industry-wide consolidation following the roll-out of Obamacare.
Thu, Jul. 23, 9:15 AM
Wed, Jul. 22, 6:30 PM
- Anthem (NYSE:ANTM) is close to a deal to buy Cigna (NYSE:CI) for around $187/share -- more than $48B total -- that could be announced as soon as tomorrow afternoon, Dow Jones is reporting.
- The move would create the country's largest insurer, with a combined current market cap of just over $80B.
- Cigna had rejected an earlier $47.5B bid as "inadequate."
- If this deal and Aetna's $34B agreement to buy Humana are both approved and finished, the five major U.S. health insurers would drop to three.
- After hours: CI +7.2%; ANTM -0.5%.
- Previously: Anthem and Cigna at the table again over possible merger (Jul. 02 2015)
Thu, Jul. 2, 10:15 AM
- According to the Wall Street Journal, health insurers Anthem (ANTM -0.4%) and Cigna (CI +1.8%) are again in talks about a possible merger. Cigna rejected Anthem's earlier $47.5B bid, calling it "inadequate and not in the best interests of Cigna's shareholders."
- Anthem's market cap is $43.6B while Cigna's is $42.3B.
Thu, Jun. 25, 10:26 AM| Thu, Jun. 25, 10:26 AM | 87 Comments
Mon, Jun. 22, 10:08 AM| Mon, Jun. 22, 10:08 AM | 1 Comment
Mon, Jun. 22, 9:18 AM
Mon, Jun. 22, 2:58 AM
- The nation's biggest health insurers, which are pursuing a series of potential megamergers due to changes in the healthcare landscape, have many market overlaps that pose challenges to competition around the country.
- On Saturday, Anthem (NYSE:ANTM) made a third offer to purchase Cigna (NYSE:CI) for $54B (although the bid was rejected), while Aetna (NYSE:AET) made a takeover offer for Humana. Those deals, if completed, would shrink the current top five insurers to a powerful big three, each with revenue on paper of more than $100B.
- UnitedHealth (NYSE:UNH), the largest industry player by revenue, has also recently jumped on the bandwagon by making a takeover approach to Aetna.
Sun, Jun. 21, 4:50 PM
- Cigna (NYSE:CI) has rejected Anthem's (NYSE:ANTM) $184/share offer for the company, saying its board unanimously determined that the offer was "inadequate."
- "We are deeply disappointed with your recent actions," Cigna's board wrote in a letter to Anthem. "We have been engaged in good faith discussions with Anthem to determine whether a potential strategic combination is in the best interests of Cigna’s shareholders.”
- Previously: Anthem goes after Cigna with $54B bid (Jun. 20 2015)
- Previously: Aetna makes takeover proposal to Humana: WSJ (Jun. 20 2015)
- Previously: Consolidation talk hits the health-insurance sector (Jun. 16 2015)
CI vs. ETF Alternatives
Other News & PR